Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy

Official Title

Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy


This is prospective research study which will include patients with recurrent or metastatic squamous cell carcinoma of the head and neck, esophagus and anal canal starting on first-line platinum based chemotherapy or any line of immunotherapy treatment.This study aims to characterize the dynamic changes in genomic, epigenetic, immune profiling and imaging data during treatment with systemic therapy. Patients will have archived tumour samples requested as well as blood samples collected at up to four time points to analyze these changes. Imaging data will be derived from patients' routine CT scans before and after treatment.

Trial Description

Primary Outcome:

  • Characterization of Genomic, epigenetic and Immune Profiling Features
Secondary Outcome:
  • Establish a Clinically Annotated Biorepository
  • Correlate Multi-Omic Results with Clinical Outcome
  • Compare HPV-Positive and HPV-Negative Cell Histologies
  • Investigate the Relationship Between Genomic Profiles and Radiomic Signatures
  • Enable Data-Sharing

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society